Gabapentin 600 mg Tablets Recalled Due to Metformin Contamination
Granules Pharmaceuticals Inc. is recalling Gabapentin Tablets 600 mg nationwide after fused Metformin ER tablets were found in bottles, creating a risk of unintended medication exposure.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. Contamination of Metformin ER tablets in Gabapentin bottles presents a risk-of-harm situation through potential unintended medication exposure, meeting the criterion for high-severity recalls without documented injury.
Plain-English summary
Granules Pharmaceuticals Inc. is recalling Gabapentin Tablets, USP, 600 mg, supplied in 500-count bottles. Three fused tablets of Metformin ER 500 mg were found in a bottle of Gabapentin, prompting this nationwide recall. Lot 1380040A (Exp. July 31, 2025) is affected.
The presence of foreign tablets in a medication bottle may result in patients taking unintended medication.
A total of 11,808 bottles have been recalled. The affected product was distributed nationwide in the United States.
If you have this medication, check your bottle for the recalled lot number (1380040A). Do not use the product if you find foreign tablets. Contact your pharmacy or healthcare provider for instructions on returning the product.
The recalled product
- Product
- GABAPENTIN (GABAPENTIN)
- Brand
- GABAPENTIN
- Manufacturer
- Granules Pharmaceuticals Inc.
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot 1380040A
- Exp. date July 31
- 2025
UPCs (2)
- 0370010228016
- 0370010227019
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · GABAPENTIN
- ModerateGabapentin blister packs recalled after unknown impurity exceeded specification
FDA (Drugs) · 2025-10-29
- ModerateGabapentin capsules recalled after stability testing found unknown impurity out of specification
FDA (Drugs) · 2025-10-29
- ModerateGabapentin Capsules 100 mg recalled for defective blister packaging
FDA (Drugs) · 2025-07-09
- ModerateGabapentin capsule bags recalled because blister packaging was inadequately sealed
FDA (Drugs) · 2025-07-09
- LowGabapentin Capsules 400 mg Recalled for Cross Contamination
FDA (Drugs) · 2025-04-16
Same manufacturer · Granules Pharmaceuticals Inc.
See all →- HighTrazodone tablets recalled over the presence of foreign tablets
FDA (Drugs) · 2026-02-11
- ModerateAmphetamine extended-release capsules 10 mg recalled over failed degradation specifications
FDA (Drugs) · 2025-10-01
- ModerateAmphetamine extended-release capsules 15 mg recalled after impurity testing failure
FDA (Drugs) · 2025-10-01
- ModerateAmphetamine extended-release capsules 20 mg recalled over impurity and degradation results
FDA (Drugs) · 2025-10-01
- ModerateAmphetamine extended-release capsules 30 mg recalled after failing impurity specifications
FDA (Drugs) · 2025-10-01
Same hazard · foreign tablets
See all →- HighBaclofen tablet bottles recalled over the presence of foreign tablets
FDA (Drugs) · 2025-12-24
- ModeratePrescription statin LIVALO tablets recalled due to foreign tablets in bottles
FDA (Drugs) · 2025-03-19
- ModerateLisinopril Tablets Recalled for Stray Amlodipine Tablet Contamination
FDA (Drugs) · 2023-11-29
- ModerateEzetimibe and Simvastatin Tablets Recalled for Defective Excipient and Foreign Tablets
FDA (Drugs) · 2021-11-17
- ModerateDr. Reddy's Ezetimibe and Simvastatin Tablets Recalled for Failed Excipient Specifications
FDA (Drugs) · 2021-11-10